MA43528A - Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih - Google Patents
Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vihInfo
- Publication number
- MA43528A MA43528A MA043528A MA43528A MA43528A MA 43528 A MA43528 A MA 43528A MA 043528 A MA043528 A MA 043528A MA 43528 A MA43528 A MA 43528A MA 43528 A MA43528 A MA 43528A
- Authority
- MA
- Morocco
- Prior art keywords
- hiv integrase
- integrase inhibitors
- tricyclic compounds
- compounds condensed
- heterocyclic tricyclic
- Prior art date
Links
- 229940099797 HIV integrase inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 239000003084 hiv integrase inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/16—Peri-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2015/100106 WO2017113288A1 (fr) | 2015-12-31 | 2015-12-31 | Composés hétérocycliques tricycliques condensés utiles en tant qu'inhibiteurs de l'intégrase du vih |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA43528A true MA43528A (fr) | 2018-11-07 |
Family
ID=57799839
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA043528A MA43528A (fr) | 2015-12-31 | 2016-12-22 | Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih |
Country Status (15)
| Country | Link |
|---|---|
| US (4) | US20170190701A1 (fr) |
| EP (1) | EP3397639B1 (fr) |
| JP (1) | JP2019500387A (fr) |
| KR (1) | KR20180095833A (fr) |
| CN (1) | CN108473494A (fr) |
| AR (1) | AR107170A1 (fr) |
| AU (1) | AU2016381072B2 (fr) |
| BR (1) | BR112018013251A2 (fr) |
| CA (1) | CA3008018A1 (fr) |
| JO (1) | JO3811B1 (fr) |
| MA (1) | MA43528A (fr) |
| MX (1) | MX2018008095A (fr) |
| RU (1) | RU2740187C2 (fr) |
| TW (1) | TW201726683A (fr) |
| WO (2) | WO2017113288A1 (fr) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10081647B2 (en) * | 2015-03-26 | 2018-09-25 | Merck Sharp & Dohme Corp. | Phosphate substituted quinolizine derivatives useful as HIV integrase inhibitors |
| JOP20190130A1 (ar) * | 2016-12-02 | 2019-06-02 | Merck Sharp & Dohme | مركبات حلقية غير متجانسة رباعية الحلقات مفيدة كمثبطات إنزيم مدمج لفيروس نقص المناعة البشرية (hiv) |
| MX384729B (es) | 2016-12-02 | 2025-03-14 | Merck Sharp & Dohme | Compuestos heterocíclicos tricíclicos útiles como inhibidores de la integrasa del virus de inmunodeficiencia humana (vih). |
| MA52367A (fr) * | 2018-04-27 | 2021-03-03 | Merck Sharp & Dohme | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih |
| RS65891B1 (sr) | 2018-05-31 | 2024-09-30 | Shionogi & Co | Policiklični karbamoilpiridonski derivati za lečenje hiv-a |
| PE20201414A1 (es) | 2018-05-31 | 2020-12-07 | Shionogi & Co | Derivado policiclico de piridona |
| US11884683B2 (en) | 2018-06-05 | 2024-01-30 | Merck Sharp & Dohme Llc | Tricyclic heterocycle compounds useful as HIV integrase inhibitors |
| WO2020086555A1 (fr) * | 2018-10-22 | 2020-04-30 | Board Of Regents Of The University Of Nebraska | Promédicaments antiviraux et nanoformulations de ceux-ci |
| LT3938047T (lt) | 2019-03-22 | 2022-10-10 | Gilead Sciences, Inc. | Tilteliniai tricikliniai karbamoilpiridono junginiai ir jų naudojimas farmacijoje |
| US20200398978A1 (en) | 2019-06-20 | 2020-12-24 | Bell Helicopter Textron Inc. | Low-drag rotor blade extension |
| TWI902729B (zh) | 2019-11-28 | 2025-11-01 | 日商鹽野義製藥股份有限公司 | 以組合整合酶阻礙劑及抗hiv藥為特徵之hiv感染症的預防及治療用醫藥 |
| WO2021107065A1 (fr) | 2019-11-28 | 2021-06-03 | 塩野義製薬株式会社 | Dérivé de pyridopyrazine polycyclique |
| BR112022015771A2 (pt) | 2020-02-24 | 2022-10-11 | Gilead Sciences Inc | Compostos tetracíclicos para tratar a infecção por hiv |
| TW202222798A (zh) | 2020-09-30 | 2022-06-16 | 美商基利科學股份有限公司 | 橋接三環胺甲醯基吡啶酮化合物及其用途 |
| PT4196479T (pt) | 2021-01-19 | 2024-01-03 | Gilead Sciences Inc | Compostos de piridotriazinas substituídos e suas utilizações |
| CA3208396A1 (fr) * | 2021-02-16 | 2022-08-25 | Timothy John Hartingh | Composes heterocycliques tetracycliques utiles en tant qu'inhibiteurs de l'integrase du vih |
| TWI856796B (zh) | 2022-04-06 | 2024-09-21 | 美商基利科學股份有限公司 | 橋聯三環胺甲醯基吡啶酮化合物及其用途 |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4338192B2 (ja) | 2001-08-10 | 2009-10-07 | 塩野義製薬株式会社 | 抗ウイルス剤 |
| ATE355064T1 (de) | 2001-10-26 | 2006-03-15 | Angeletti P Ist Richerche Bio | Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase |
| HU230248B1 (hu) | 2001-10-26 | 2015-11-30 | Msd Italia S.R.L. | N-szubsztituált hidroxipirimidinon-karboxamid HIV-integráz inhibitorok |
| CA2472372C (fr) | 2002-01-17 | 2010-08-17 | Melissa Egbertson | Carboxamides hydroxynaphthyridinone utiles comme inhibiteurs de l'integrase du vih |
| MXPA05007010A (es) | 2002-12-27 | 2005-08-18 | Angeletti P Ist Richerche Bio | Tetrahidro-4h-pirido[1,2-a]pirimidinas y compuestos relacionados utiles como inhibidores de la integrasa del virus de inmunodeficiencia humana. |
| WO2004062613A2 (fr) | 2003-01-13 | 2004-07-29 | Bristol-Myers Squibb Company | Inhibiteurs d'integrase hiv |
| US7037908B2 (en) | 2003-04-24 | 2006-05-02 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| TW200510425A (en) | 2003-08-13 | 2005-03-16 | Japan Tobacco Inc | Nitrogen-containing fused ring compound and use thereof as HIV integrase inhibitor |
| AR046938A1 (es) | 2003-12-12 | 2006-01-04 | Merck & Co Inc | Procedimiento para preparar hexahidropirimido[1,2-a]azepin-2-carboxilatos y compuetos similares |
| TW200526635A (en) | 2003-12-22 | 2005-08-16 | Shionogi & Co | Hydroxypyrimidinone derivative having HIV integrase inhibitory activity |
| WO2005087766A1 (fr) * | 2004-03-09 | 2005-09-22 | Istituto Di Ricerche Di Biologia Molecolare P Angeletti Spa | Inhibiteurs de l'intégrase du vih |
| US7273859B2 (en) | 2004-05-12 | 2007-09-25 | Bristol-Myers Squibb Company | HIV integrase inhibitors: cyclic pyrimidinone compounds |
| US7115601B2 (en) | 2004-05-18 | 2006-10-03 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7173022B2 (en) | 2004-05-28 | 2007-02-06 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7176196B2 (en) | 2004-05-28 | 2007-02-13 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7192948B2 (en) | 2004-05-28 | 2007-03-20 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| US7157447B2 (en) | 2004-05-28 | 2007-01-02 | Bristol-Myers Squibb Company | Bicyclic heterocycles as HIV integrase inhibitors |
| JP5116660B2 (ja) | 2005-03-31 | 2013-01-09 | イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・エルレ・エルレ | Hivインテグラーゼ阻害剤 |
| US7494984B2 (en) | 2005-08-31 | 2009-02-24 | Bristol-Myers Squibb Company | Substituted imidazo[1,2-a]pyrimidines as HIV viral DNA integrase inhibitors |
| CN101346376A (zh) * | 2005-10-27 | 2009-01-14 | 盐野义制药株式会社 | 具有hiv整合酶抑制活性的多环性氨基甲酰基吡啶酮衍生物 |
| US7897592B2 (en) | 2005-11-15 | 2011-03-01 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US7902182B2 (en) | 2005-11-16 | 2011-03-08 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| US8039458B2 (en) | 2005-11-17 | 2011-10-18 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| WO2007143446A1 (fr) | 2006-05-30 | 2007-12-13 | Bristol-Myers Squibb Company | Composés hétérotricycliques spiro-condensés utilisés en tant qu'inhibiteurs de la vih intégrase |
| US7893055B2 (en) | 2006-06-28 | 2011-02-22 | Bristol-Myers Squibb Company | HIV integrase inhibitors |
| PT2344495E (pt) * | 2008-10-07 | 2015-04-01 | Actelion Pharmaceuticals Ltd | Compostos antibióticos de oxazolidinona tricíclica |
| NZ598766A (en) | 2009-10-13 | 2013-09-27 | Elanco Animal Health Ireland | Macrocyclic integrase inhibitors |
| EP2552923B1 (fr) | 2010-04-02 | 2014-03-26 | Janssen R&D Ireland | Inhibiteurs de l'intégrase macrocyclique |
| WO2014172188A2 (fr) * | 2013-04-16 | 2014-10-23 | Merck Sharp & Dohme Corp. | Composés dérivés de 4-pyridone et leurs utilisations en tant qu'inhibiteurs de la vih intégrase |
| HUE036384T2 (hu) * | 2013-05-17 | 2018-07-30 | Merck Sharp & Dohme | Fúzionált triciklusos heterociklikus vegyületek mint HIV integráz inhibitorok |
-
2015
- 2015-12-31 WO PCT/CN2015/100106 patent/WO2017113288A1/fr not_active Ceased
-
2016
- 2016-12-22 CA CA3008018A patent/CA3008018A1/fr not_active Abandoned
- 2016-12-22 JP JP2018534101A patent/JP2019500387A/ja active Pending
- 2016-12-22 KR KR1020187018217A patent/KR20180095833A/ko not_active Withdrawn
- 2016-12-22 MA MA043528A patent/MA43528A/fr unknown
- 2016-12-22 CN CN201680073126.9A patent/CN108473494A/zh active Pending
- 2016-12-22 WO PCT/US2016/068173 patent/WO2017116928A1/fr not_active Ceased
- 2016-12-22 MX MX2018008095A patent/MX2018008095A/es unknown
- 2016-12-22 EP EP16826561.9A patent/EP3397639B1/fr active Active
- 2016-12-22 AR ARP160103990A patent/AR107170A1/es unknown
- 2016-12-22 TW TW105142826A patent/TW201726683A/zh unknown
- 2016-12-22 US US15/387,732 patent/US20170190701A1/en not_active Abandoned
- 2016-12-22 RU RU2018127728A patent/RU2740187C2/ru active
- 2016-12-22 BR BR112018013251A patent/BR112018013251A2/pt not_active Application Discontinuation
- 2016-12-22 JO JOP/2016/0271A patent/JO3811B1/ar active
- 2016-12-22 AU AU2016381072A patent/AU2016381072B2/en not_active Ceased
-
2017
- 2017-12-13 US US15/840,017 patent/US20180099967A1/en not_active Abandoned
-
2019
- 2019-06-27 US US16/454,857 patent/US20190322666A1/en not_active Abandoned
-
2020
- 2020-10-27 US US17/081,094 patent/US20210040096A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP3397639A1 (fr) | 2018-11-07 |
| BR112018013251A2 (pt) | 2018-12-04 |
| MX2018008095A (es) | 2018-08-23 |
| WO2017113288A1 (fr) | 2017-07-06 |
| US20170190701A1 (en) | 2017-07-06 |
| AU2016381072B2 (en) | 2020-11-26 |
| JO3811B1 (ar) | 2021-01-31 |
| EP3397639B1 (fr) | 2022-02-23 |
| KR20180095833A (ko) | 2018-08-28 |
| JP2019500387A (ja) | 2019-01-10 |
| AU2016381072A1 (en) | 2018-05-31 |
| US20190322666A1 (en) | 2019-10-24 |
| RU2018127728A3 (fr) | 2020-02-14 |
| TW201726683A (zh) | 2017-08-01 |
| CA3008018A1 (fr) | 2017-07-06 |
| WO2017116928A1 (fr) | 2017-07-06 |
| CN108473494A (zh) | 2018-08-31 |
| US20210040096A1 (en) | 2021-02-11 |
| RU2740187C2 (ru) | 2021-01-12 |
| AR107170A1 (es) | 2018-03-28 |
| US20180099967A1 (en) | 2018-04-12 |
| RU2018127728A (ru) | 2020-02-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA43528A (fr) | Composés hétérocycliques tricycliques condensés à titre d'inhibiteurs de l'intégrase du vih | |
| DK3735299T3 (da) | Kondenserede ringforbindelser | |
| EP3464275A4 (fr) | Composés inhibiteurs de l'egfr | |
| MA47576A (fr) | Composés inhibiteurs d'oga bicyclique | |
| PT3122752T (pt) | Derivados de nucleósido substituídos em 4' como inibidores de transcriptase reversa de vih | |
| MA51878A (fr) | Composés d'aminothiazole en tant qu'inhibiteurs de c-kit | |
| PT3523390T (pt) | Utilização de composições à base de tetrafluoropropeno | |
| EP3752144A4 (fr) | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| EP3277381C0 (fr) | Dérivés de nitrobenzyle d'agents anticancéreux | |
| EP3548031A4 (fr) | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| MA47013A (fr) | Composés benzolactames utilisés en tant qu'inhibiteurs de protéine kinase | |
| MA43169A (fr) | Composés hétérocycliques utilisés en tant qu'inhibiteurs de pi3k-gamma | |
| EP2997033A4 (fr) | Composés hétérocycliques tricycliques fusionnés utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| MA40587A (fr) | Composés d'aminopyrimidinyle en tant qu'inhibiteurs de jak | |
| EP3353278A4 (fr) | Préparation d'échantillons pour des types d'échantillons compliqués | |
| MA46242A (fr) | Composés inhibiteurs de bêta-lactamase | |
| EP3337787A4 (fr) | Composés pyrazolo hétérocycliques condensés comme inhibiteurs d'erk | |
| EP3784241A4 (fr) | Composés hétérocycliques tricycliques utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| EP3377065A4 (fr) | Dérivés de pyridotriazine spirocyclique utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| DK3130592T3 (da) | ANALOGER AF 4H-PYRAZOLO[1,5-á]BENZIMIDAZOL-FORBINDELSER SOM PARPINHIBITORER | |
| EP3377066A4 (fr) | Dérivés de pyridotriazine amido-substitués utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| MA47420A (fr) | Composés inhibiteurs d'oga | |
| EP3389380A4 (fr) | Dérivés de quinolizine spirocycliques utiles en tant qu'inhibiteurs de l'intégrase du vih | |
| DK3386991T3 (da) | Polycykliske forbindelser som inhibitorer af bruton's tyrosinkinase | |
| EP3630775A4 (fr) | Cycles 6-5 fusionnés utilisés en tant qu'inhibiteurs de c5a |